Accessibility Menu
 
Eledon Pharmaceuticals logo

Eledon Pharmaceuticals

(NASDAQ) ELDN

Current Price$3.19
Market Cap$244.24M
Since IPO (2017)-97%
5 Year-72%
1 Year+10%
1 Month+20%

Eledon Pharmaceuticals Financials at a Glance

Market Cap

$244.24M

Revenue (TTM)

$0.00

Net Income (TTM)

$45.62M

EPS (TTM)

$-0.59

P/E Ratio

-5.42

Dividend

$0.00

Beta (Volatility)

0.80 (Low)

Price

$3.19

Volume

13,953

Open

$3.28

Previous Close

$3.19

Daily Range

$3.15 - $3.30

52-Week Range

$1.35 - $4.60

ELDN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eledon Pharmaceuticals

Industry

Biotechnology

Employees

33

CEO

David-Alexandre C. Gros, MD, MBA

Website

eledon.com

Headquarters

Irvine, CA 92612, US

ELDN Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-36%

Return on Capital

-38%

Return on Assets

-19%

Earnings Yield

-18.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$244.24M

Shares Outstanding

75.85M

Volume

13.95K

Short Interest

0.00%

Avg. Volume

1.06M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$83.25M

EBITDA

$83.25M

Operating Cash Flow

$62.34M

Capital Expenditure

$0.00

Free Cash Flow

$62.34M

Cash & ST Invst.

$133.34M

Total Debt

$641.00K

Eledon Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$244.24M

N/A

Market Cap/Employee

$7.88M

N/A

Employees

31

N/A

Net Income

$10.45M

+76.6%

EBITDA

$21.48M

+51.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$132.69M

-4.7%

Accounts Receivable

$514.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$283.00K

-55.8%

Short Term Debt

$358.00K

+14.0%

Return on Assets

-19.20%

N/A

Return on Invested Capital

-37.97%

N/A

Free Cash Flow

$14.09M

+25.8%

Operating Cash Flow

$14.09M

+25.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYGRVoyager Therapeutics, Inc.
$3.94+2.60%
ABEOAbeona Therapeutics Inc.
$5.19+2.57%
ACHVAchieve Life Sciences, Inc.
$3.61+0.84%
EDITEditas Medicine, Inc.
$3.39+5.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.54+0.07%
TQQQProShares Trust - ProShares UltraPro Qqq
$53.41+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.91-0.08%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$62.02-0.05%

Questions About ELDN

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.